Show simple item record

dc.contributor.authorSastre, Beatriz
dc.contributor.authorGarcía-García, María Luz
dc.contributor.authorCañas, José Antonio
dc.contributor.authorCalvo, Cristina
dc.contributor.authorRodrigo-Muñoz, José Manuel
dc.contributor.authorCasas, Inmaculada 
dc.contributor.authorMahíllo-Fernández, Ignacio
dc.contributor.authorDel Pozo, Victoria
dc.date.accessioned2022-04-06T11:27:46Z
dc.date.available2022-04-06T11:27:46Z
dc.date.issued2021
dc.identifier.citationPediatr Allergy Immunol. 2021 ;32(1):51-59.es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/13932
dc.description.abstractBackground: Recurrent wheezing (RW) is frequently developed in infants that have suffered bronchiolitis (BCH) during first months of life, but the immune mechanism underlying is not clear. The goal was to analyze the innate immune response that characterizes BCH and RW. Methods: Ninety-eight and seventy hospitalized infants with BCH or RW diagnosis, respectively, were included. Nasopharyngeal aspirate (NPA) was processed. Cellular pellet was employed to evaluate type 2 innate lymphoid cells (ILC2) by flow cytometry and mRNA expression assays by semi-quantitative real-time PCR (qRT-PCR). In supernatant, twenty-seven pro-inflammatory and immunomodulatory factors, as well as lipid mediators and nitrites, were evaluated by ELISA and Luminex. Results: Bronchiolitis patients showed higher ILC2 percentage compared with RW (P < .05). Also, ST2+ /ILC2 percentage was higher in the BCH group than in the RW group (P < .01). TLR3, IL33, IFNG, IL10, and FLG mRNA levels were significantly increased in BCH vs RW (P < .05). In supernatant, no significant differences were reached, observing similar levels of parameters linked to vascular damage, monocyte activation, and fibroblast growth. Prostaglandin E2 and cysteinyl leukotrienes C4 were evaluated; a significant difference was only found in their ratio. Conclusion: Bronchiolitis is associated with elevated nasal percentage of ILC2. This cellular population could be the key element in the differential immune response between BCH and RW which share some mechanisms such us monocyte activation, vascular damage, and fibroblast repair. Lipid mediators could play a role in the evolution of the disease later in life through innate lymphoid cells.es_ES
dc.description.sponsorshipThis study has been partially supported by FIS (Fondo de Investigación Sanitaria—Spanish Health Research Fund) Grants PI15/00803, FI16/00036, PI15CIII/00028, and FEDER Funds (Fondo Europeo de Desarrollo Regional); Alfonso X El Sabio University Grant: VIII Convocatoria Santander‐UAX; and CIBER de Enfermedades Respiratorias (CIBERES), a Carlos III Institute of Health Initiative.es_ES
dc.language.isoenges_ES
dc.publisherWiley es_ES
dc.relation.isversionofPublisher's versiones_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectBronchiolitises_ES
dc.subjectLipid mediatorses_ES
dc.subjectRecurrent wheezinges_ES
dc.subjectType 2 innate lymphoid cells (ILC2)es_ES
dc.subjectImmune responsees_ES
dc.titleBronchiolitis and recurrent wheezing are distinguished by type 2 innate lymphoid cells and immune responsees_ES
dc.typeArtículoes_ES
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.identifier.pubmedID32628310es_ES
dc.format.volume32es_ES
dc.format.number1es_ES
dc.format.page51-59es_ES
dc.identifier.doi10.1111/pai.13317es_ES
dc.contributor.funderInstituto de Salud Carlos III es_ES
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF)es_ES
dc.contributor.funderAlfonso X el Sabio University (España)es_ES
dc.contributor.funderCentro de Investigación Biomédica en Red - CIBERES (Enfermedades Respiratorias)es_ES
dc.description.peerreviewedes_ES
dc.identifier.e-issn1399-3038es_ES
dc.relation.publisherversionhttps://doi.org/10.1111/pai.13317es_ES
dc.identifier.journalPediatric Allergy and Immunologyes_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.relation.projectFISinfo:fis/Instituto de Salud Carlos III/null/null/Subprograma de proyectos de investigacion en salud (AES 2015). Modalidad proyectos en salud. (2015)/PI15/00803es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/PI15CIII/00028es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/FI16/00036es_ES


Files in this item

Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
This item is licensed under a: Attribution-NonCommercial-NoDerivatives 4.0 Internacional